Upload Image (Max 20MB per Image)
GlaxoSmithKline (GSK) and Theravance have announced the regulatory submissions for furoate FF/vilanterol VI (FF/VI) to treat chronic obstructive pulmonary disease (COPD) in the US and Europe. The companies also announced regulatory ...
Tags: chronic obstructive pulmonary disease, asthma therapy